Video

Dr. Velcheti on the Importance of Real-World Data in NSCLC

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

Vamsidhar Velcheti, MD, the director of thoracic medical oncology at NYU Langone Health Perlmutter Cancer Center, discusses the importance of real-world data for patients with non–small cell lung cancer.

A gap can sometimes exist between clinical trial data and every day clinical practice, Velcheti says. The expectation of treatments from clinical trials following their FDA approval may not necessarily reflect outcomes in the real world, he continues. 

When physicians treat patients in clinical practice, they may not be the same as the homogeneous patient population that is normally included in clinical trials. Due to this, it is important to validate clinical trial findings in a real-world setting to ensure the treatment is most applicable, Velcheti concludes.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.